Clarke SJ - Search Results

1

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.

Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frödin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Mauro DJ, Watkins DJ. Sclafani F, et al. Among authors: clarke sj. J Natl Cancer Inst. 2015 Sep 23;107(12):djv258. doi: 10.1093/jnci/djv258. Print 2015 Dec. J Natl Cancer Inst. 2015. PMID: 26405092 Clinical Trial.

2

Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials.

Cunningham D, Zalcberg J, Maroun J, James R, Clarke S, Maughan TS, Vincent M, Schulz J, González Barón M, Facchini T. Cunningham D, et al. Eur J Cancer. 2002 Mar;38(4):478-86. doi: 10.1016/s0959-8049(01)00413-0. Eur J Cancer. 2002. PMID: 11872339 Review.

3

A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer.

Tobin PJ, Beale P, Noney L, Liddell S, Rivory LP, Clarke S. Tobin PJ, et al. Cancer Chemother Pharmacol. 2006 Feb;57(3):309-16. doi: 10.1007/s00280-005-0053-0. Epub 2005 Jul 8. Cancer Chemother Pharmacol. 2006. PMID: 16003560 Clinical Trial.

4

A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer.

Sharma R, Rivory L, Beale P, Ong S, Horvath L, Clarke SJ. Sharma R, et al. Among authors: clarke sj. Br J Cancer. 2006 Apr 10;94(7):964-8. doi: 10.1038/sj.bjc.6603049. Br J Cancer. 2006. PMID: 16552436 Free PMC article. Clinical Trial.

5

Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients--analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO.

Sharma R, Cunningham D, Smith P, Robertson G, Dent O, Clarke SJ. Sharma R, et al. Among authors: clarke sj. BMC Cancer. 2009 May 18;9:153. doi: 10.1186/1471-2407-9-153. BMC Cancer. 2009. PMID: 19450285 Free PMC article. Clinical Trial.

6

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.

Chua W, Goldstein D, Lee CK, Dhillon H, Michael M, Mitchell P, Clarke SJ, Iacopetta B. Chua W, et al. Among authors: clarke sj. Br J Cancer. 2009 Sep 15;101(6):998-1004. doi: 10.1038/sj.bjc.6605239. Epub 2009 Aug 11. Br J Cancer. 2009. PMID: 19672255 Free PMC article.

7

Cetuximab-associated pulmonary toxicity.

Chua W, Peters M, Loneragan R, Clarke S. Chua W, et al. Clin Colorectal Cancer. 2009 Apr;8(2):118-20. doi: 10.3816/CCC.2009.n.019. Clin Colorectal Cancer. 2009. PMID: 19739274

8

Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer.

Chua W, Moore MM, Charles KA, Clarke SJ. Chua W, et al. Among authors: clarke sj. Curr Opin Mol Ther. 2009 Dec;11(6):611-22. Curr Opin Mol Ther. 2009. PMID: 20072938 Review.

9

Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer.

Chua W, Kho PS, Moore MM, Charles KA, Clarke SJ. Chua W, et al. Among authors: clarke sj. Crit Rev Oncol Hematol. 2011 Sep;79(3):224-50. doi: 10.1016/j.critrevonc.2010.07.012. Epub 2010 Aug 16. Crit Rev Oncol Hematol. 2011. PMID: 20719530 Review.

10

Reporting clinical trial information: colorectal cancer trials at Sydney Cancer Centre.

Chua W, Horvath L, Beale P, Clarke SJ. Chua W, et al. Among authors: clarke sj. Intern Med J. 2012 Apr;42(4):416-21. doi: 10.1111/j.1445-5994.2011.02441.x. Intern Med J. 2012. PMID: 21299781

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

352 results

Search Page